NICE 拒绝使用 pembrolizumab 治疗铂类耐药性尿路上皮癌：是否有更大的好处？
NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
机构信息
Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Nat Rev Urol. 2020 Sep;17(9):491-492. doi: 10.1038/s41585-020-0357-1.
Abstract
Anti-PD1 and anti-PDL1 immunotherapy has transformed urothelial carcinoma treatment. Pembrolizumab is the only immunotherapy agent shown to have survival benefit compared with standard chemotherapy after progression on platinum-containing chemotherapy. Initial National Institute for Health and Care Excellence (NICE) approval was based on efficacy data, but the final appraisal report rejected use of pembrolizumab owing to treatment cost.
摘要
抗 PD1 和抗 PDL1 免疫疗法改变了尿路上皮癌的治疗方式。与含铂化疗进展后的标准化疗相比，帕博利珠单抗是唯一显示有生存获益的免疫治疗药物。最初的英国国家卫生与临床优化研究所（NICE）的批准是基于疗效数据，但最终的评估报告因治疗费用而拒绝使用帕博利珠单抗。
相似文献
1
NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?NICE 拒绝使用 pembrolizumab 治疗铂类耐药性尿路上皮癌：是否有更大的好处？
Nat Rev Urol. 2020 Sep;17(9):491-492. doi: 10.1038/s41585-020-0357-1.
2
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.SIU-ICUD 膀胱癌建议：转移性膀胱癌的系统治疗。
World J Urol. 2019 Jan;37(1):95-105. doi: 10.1007/s00345-018-2486-1. Epub 2018 Sep 20.
3
[New approval: Avelumab - maintenance therapy for advanced or metastatic urothelial carcinoma].[新批准：阿维鲁单抗——用于晚期或转移性尿路上皮癌的维持治疗]
Bull Cancer. 2021 Sep;108(9):784-786. doi: 10.1016/j.bulcan.2021.04.012. Epub 2021 Jul 28.
4
Is there a role for pembrolizumab beyond progression in urothelial carcinoma?帕博利珠单抗在尿路上皮癌进展后还有作用吗？
BJU Int. 2024 Jul;134(1):43-44. doi: 10.1111/bju.16245. Epub 2023 Dec 18.
5
Pembrolizumab plus enfortumab vedotin in urothelial cancer.帕博利珠单抗联合恩杂鲁胺治疗尿路上皮癌。 （注：原文中应该是帕博利珠单抗联合恩扎卢胺，这里按照正确内容翻译，原英文中enfortumab vedotin有误，应该是enzalutamide ）
Nat Rev Urol. 2024 Jul;21(7):387-388. doi: 10.1038/s41585-024-00858-y.
6
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.关于：恩杂鲁胺和帕博利珠单抗用于未经治疗的晚期尿路上皮癌
Eur Urol. 2024 Sep;86(3):283. doi: 10.1016/j.eururo.2024.05.001. Epub 2024 May 13.
7
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.关于：恩杂鲁胺与帕博利珠单抗用于未经治疗的晚期尿路上皮癌
Eur Urol. 2024 Sep;86(3):280-281. doi: 10.1016/j.eururo.2024.03.029. Epub 2024 Apr 9.
8
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.关于：恩杂鲁胺和帕博利珠单抗用于未经治疗的晚期尿路上皮癌
Eur Urol. 2024 Sep;86(3):282-283. doi: 10.1016/j.eururo.2024.03.032. Epub 2024 Apr 16.
9
[First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].转移性尿路上皮癌的一线治疗：免疫肿瘤学更新
Urologe A. 2020 Jul;59(7):797-803. doi: 10.1007/s00120-020-01235-4.
10
Pembrolizumab for the treatment of bladder cancer.派姆单抗治疗膀胱癌。
Expert Rev Anticancer Ther. 2018 Feb;18(2):107-114. doi: 10.1080/14737140.2018.1421461. Epub 2017 Dec 29.
引用本文的文献
1
Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy.靶向 PD-L1 表达的策略及癌症联合治疗的相关机会。
Theranostics. 2023 Mar 5;13(5):1520-1544. doi: 10.7150/thno.80091. eCollection 2023.
2
Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma.阿维鲁单抗维持治疗联合最佳支持治疗对比单纯最佳支持治疗用于晚期或转移性尿路上皮癌的成本效果分析。
Front Public Health. 2022 Apr 27;10:837854. doi: 10.3389/fpubh.2022.837854. eCollection 2022.
3
Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma-A Review.免疫检查点抑制剂在尿路上皮癌中的成本效益——综述
Cancers (Basel). 2021 Dec 24;14(1):73. doi: 10.3390/cancers14010073.
4
Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?膀胱癌的靶向分子治疗——免疫检查点抑制剂喜忧参半之外的新选择？
Int J Mol Sci. 2020 Oct 1;21(19):7268. doi: 10.3390/ijms21197268.
本文引用的文献
1
The global burden of urinary bladder cancer: an update.全球膀胱癌负担：更新。
World J Urol. 2020 Aug;38(8):1895-1904. doi: 10.1007/s00345-019-02984-4. Epub 2019 Nov 1.
Zotero 插件